Aerie wins FDA nod for second glaucoma drug

This article was originally published here

Aerie Pharmaceuticals - updated logoAerie Pharmaceuticals (NSDQ:AERI) said this week that the FDA approved the company’s once-daily eye drop Rocklatan for the treatment of elevated intraocular pressure in people with open-angle glaucoma or ocular hypertension.

The Durham, N.C.-based company’s product is a fixed-dose combination of latanoprost and netarsudil – the active ingredient in Aerie’s first drug, Rhopressa.

Get the full story at our sister site, Drug Delivery Business News.

The post Aerie wins FDA nod for second glaucoma drug appeared first on MassDevice.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply